Welcome to our dedicated page for Alterity Therapeutics SEC filings (Ticker: ATHE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alterity Therapeutics Limited filings document a foreign private issuer and development-stage biotechnology company reporting through Form 6-K and incorporated reports tied to Form S-8 and Form F-3 registration statements. The filings record ATH434 and MSA development updates, bioMUSE biomarker publications, FDA meeting communications, medical conference presentations, and Appendix 4C quarterly cash flow and activity reports.
Other disclosures cover shareholder meeting and proxy materials, substantial holding notices, share consolidation or split notices, board and governance changes, and capital-structure matters for securities traded as ASX: ATH and NASDAQ: ATHE.
Alterity Therapeutics has completed a consolidation of its issued capital on a fifty (50) to one (1) basis, as previously approved by shareholders. After the consolidation, the company has 217,508,862 ordinary fully paid shares on issue, along with multiple listed and unlisted option series with various expiries and exercise prices.
The company confirms post-consolidation holdings for shareholders and option holders, with any fractional entitlements rounded up to the nearest whole security. Normal T+2 trading in the consolidated shares has commenced on the ASX under code ATH. Alterity remains a clinical-stage biotechnology company focused on Multiple System Atrophy, preparing to initiate a Phase 3 pivotal trial for its lead asset ATH434.
Alterity Therapeutics reports a successful End-of-Phase 2 meeting with the U.S. FDA, securing alignment on the pivotal Phase 3 program for its lead candidate ATH434 in Multiple System Atrophy (MSA), a rare neurodegenerative disease with no approved therapy.
The FDA agreed the Phase 3 design can support a potential New Drug Application, including the study population, 12‑month treatment duration, and primary endpoint using the 11‑item UMSARS Part I scale. The agency also backed a 50 mg twice‑daily dose, which in Phase 2 produced clinically and statistically significant efficacy with 48% slowing of disease progression versus placebo.
Phase 3 is planned as a randomized, double‑blind, placebo‑controlled trial enrolling approximately 200 participants with clinical and biomarker evidence of MSA, targeting initiation of trial activities by year‑end 2026. ATH434 already holds Fast Track and Orphan Drug Designations for MSA, and positive Phase 2 data showed robust efficacy, target engagement, and a favorable safety profile.
Alterity Therapeutics Limited is implementing a 1 for 50 consolidation of its share capital following shareholder approval at an Extraordinary General Meeting on 29 May 2026. This reduces each holder’s number of shares, with fractional entitlements rounded up to at least one security and the share price adjusted accordingly.
From 3 June to the close of trading on 11 June 2026, Alterity securities trade on the ASX on a post-consolidation, deferred settlement basis under temporary code “ATHDA”, with a record date of 4 June 2026. Listed options “ATHO” and “ATHOA” temporarily trade as “ATHDB” and “ATHDC”. Normal T+2 trading under the “ATH” code resumes on 12 June 2026.
Alterity Therapeutics Limited, a development stage enterprise listed on ASX and Nasdaq, filed a Form 6-K to report an administrative change. The company has changed its registered office address to Level 15, 500 Collins Street, Melbourne, VIC 3000, effective 3 June 2026. The report notes that this Form 6-K is incorporated by reference into several existing Form S-8 and Form F-3 registration statements.
Alterity Therapeutics Limited reports the results of its 2026 Extraordinary General Meeting, confirming that shareholders passed the resolutions presented at the meeting held on 29 May 2026.
The company is a clinical stage biotechnology business focused on disease-modifying therapies for Multiple System Atrophy and related Parkinsonian disorders. Its lead asset, ATH434, has shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial in MSA and additional positive data in an open label Phase 2 trial in advanced MSA. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA and continues to develop a broader pipeline of patentable compounds targeting neurological disease pathology.
Alterity Therapeutics filed a Form 6-K highlighting new clinical data that support advancing its lead drug candidate ATH434 into a Phase 3 trial for Multiple System Atrophy (MSA), a rare neurodegenerative disease with no approved disease‑modifying therapies.
A 12‑month randomized, double‑blind, placebo‑controlled Phase 2 trial in 77 adults with MSA showed clinically and statistically significant improvement on the modified UMSARS Part I functional scale versus placebo, with consistent trends across additional motor and symptom measures and increased activity captured by wearable sensors. Imaging and biomarker data indicated reduced iron accumulation in affected brain regions and signs of preserved brain volume, and ATH434 was well tolerated with no serious adverse events attributed to the drug.
Alterity also emphasized ongoing work from its bioMUSE natural history study to refine biomarker selection and trial design. ATH434 has Fast Track and Orphan Drug Designations for MSA, and an End‑of‑Phase 2 FDA meeting is planned for mid‑2026 to confirm the Phase 3 development path.